Analysis of the Related Risk Factors of Cerebral AVM Hemorrhage

[Analysis of the Related Risk Factors of Cerebral AVM Hemorrhage and the Relationship Between EPCs and SDF-1 in Brain AVM]

Objective: To explore the risk factors associated human brain hemorrhage in cerebral arteriovenous malformations (AVM) and the relationship between endothelial progenitor cells (EPC) content and stromal cell-derived factor-1 (SDF-1) at different ages.


Methods: A retrospective analysis performed on 130 patients with cerebral AVM who underwent surgical treatment from May 2012 to October 2018. Univariate and multivariate logistic analysis is used to investigate the risk factors associated with brain AVM hemorrhage. Forty specimens of the human brain AVM paraffin harvested from 24 cases of patients with cerebral hemorrhage and 16 cases of non-bleeding patients Paraffin brain cerebral cortex samples from eight patients with epilepsy during the same period selected as controls. positive expression of CD34 and vascular endothelial growth factor receptor 2 (KDR2) in brain tissue samples from both groups were used to identify EPC. Immunofluorescence double staining is used to KDR2 and CD34 positive localization to determine the EPC localization and detection of SDF-1 expression is done.


Results: The size of a brain AVM <3 cm, deep brain AVM and single venous drainage is an independent risk factor for brain AVM hemorrhage. The results of immunohistochemistry showed that CD34 and KDR2 expressed in brain AVM group, but not in the control group. Double immunofluorescence staining showed that EPC especially near the edges of blood vessel walls, while SDF-1 can co-stain with alpha-smooth muscle actin (α-SMA) positive cells and CD31 positive cells. SDF-1 expression in the tissues of the brain AVM higher than the control group.

There are significant differences in the number of EPC among patients of different ages (P <0.05). There is no significant difference between groups in the EPC brain hemorrhage and non-bleeding group (P> 0.05).
Conclusion: Brain AVM (<3 cm), single and AVM venous drainage of the brain in an independent risk factor for brain AVM hemorrhage. In the human brain AVM, EPC appears high level but decrease with age, which may play a role in vascular remodeling in AVM.

 [Analysis of the Related Risk Factors of Cerebral AVM Hemorrhage and the Relationship Between EPCs and SDF-<em>1</em> in <em>Brain</em> AVM]
[Analysis of the Related Risk Factors of Cerebral AVM Hemorrhage and the Relationship Between EPCs and SDF-1 in Brain AVM]

Brain co-delivery -targeted of β-amyloid converting enzyme one shRNA and epigallocatechin-3-gallate by multifunctional nanocarriers for the treatment of Alzheimer’s disease

progressive memory loss and cognitive dysfunction clinical hallmark of Alzheimer’s disease (AD). As a possible treatment for AD, we develop epigallocatechin-3-gallate (EGCG) and β-site amyloid precursor protein (APP) antisense splitting enzyme 1 (BACE1-AS) shRNA plasmid-encoded. The plasmid is loaded into RVG29 multifunctional peptide-targeted nanoparticles (NP) (REGS-PN).

NP polymers were characterized by flow cytometry, biocompatibility tests, pharmacokinetic analysis, Western blot analysis, and Morris water maze (MWM) test. Differences in plasma and brain accumulation of NP after intravenous administration showed a significantly longer circulation time for EGS-REGS-PN and PN in the bloodstream. In contrast, free EGCG quickly eliminated from circulation. REGS-PM managed to travel through the blood-brain barrier and is present in higher concentrations in the brain compared with both non-targeted NP and free EGCG.

REGS-PN administration to APPswe / PS1dE9 double transgenic mice (APP / PS1 mice) resulted in downregulation of a key enzyme in the formation of amyloid-β (BACE1) and amyloid beta, suggesting a synergistic therapeutic activity. MWM test revealed that the simultaneous delivery of gene therapy and EGCG (REGS-PN) greatly enhance the ability of learning and spatial memory APP / PS1 mice and wild-type mice compared with EGCG-treated group free.

With these results, we propose that the co-delivery of therapeutic genes (shRNA) and EGCG in multifunctional nanocarrier can achieve a higher therapeutic concentrations in the brain and could be a very good strategy for the treatment of AD.

 

Een reactie achterlaten

Je e-mailadres zal niet getoond worden. Vereiste velden zijn gemarkeerd met *